ARCHIVES

Phase III Trial: Panobinostat Increases PFS by Four Months

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Healthcare Utilization Figures More Than Biology In Disparity

April 30, 2010

Clinical Trials Approved By NCI CTEP Last Month

January 28, 2011

Cancer Program Depend On Vitality Of Centers, Broder ells DCPC Board

May 12, 1989

In Brief : Patricia LoRusso Named Associate Director Of Innovative Medicine at Yale Cancer Center

June 20, 2014

With NIH “Accountability” As Background, Advocates Support Budget Increases.

March 30, 2001

Cancer, AIDS Patient Advocates List Drug Development Concerns

May 12, 1989